logo 600X600.png
Clinical Trial Software Market Surges to US$ 2.3 Billion by 2031, Propelled by 14.3% CAGR, States CoherentMI
10 sept. 2024 11h01 HE | CMI
Burlingame, Sept. 10, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Clinical Trial Software Market is estimated to value at US$ 0.9 Billion in the year 2024, and is anticipated to...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical Appoints Brikkelle Thompson as Senior Vice President of Human Resources
10 sept. 2024 07h00 HE | Lifecore Biomedical, Inc.
CHASKA, Minn., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization...
ONL logo.jpg
ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight
10 sept. 2024 07h00 HE | ONL Therapeutics
ANN ARBOR, Mich., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
The Highly Anticipat
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
09 sept. 2024 10h20 HE | Spherix Global Insights
EXTON, PA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market....
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results
05 sept. 2024 10h52 HE | Boehringer Ingelheim
Ingelheim, Germany and Basel, Switzerland, September 5, 2024 – Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record |...
Transparency Market Research
Hepatitis Therapeutics Market Size worth USD 21.9 Billion by 2031, with a CAGR of 3.6% - Transparency Market Research, Inc.
04 sept. 2024 06h29 HE | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 04, 2024 (GLOBE NEWSWIRE) -- As per the report published by Transparency Market Research, the global hepatitis...
OLON GROUP
Olon Continues its Growth Path and Announces a New Acquisition
04 sept. 2024 05h00 HE | Olon SpA
MILAN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The acquisition plan involves a complete operational integration of Huvepharma Italia Srl and a plan to revive the production potential of the Garessio...
Avid Logo June 2022.jpg
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024
03 sept. 2024 16h05 HE | Avid Bioservices, Inc
TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Ipsen's Iqirvo Shows
Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi
29 août 2024 14h14 HE | Spherix Global Insights
EXTON, PA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- The past few months have ushered in a new era of treatment for patients suffering from primary biliary cholangitis (PBC), marked by the approval of...
Hematologists Highli
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising Advances in Gene Therapies
28 août 2024 10h14 HE | Spherix Global Insights
EXTON, PA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Despite advancements in treatments, sickle cell disease and thalassemia continue to present significant challenges for patients and healthcare providers....